September 5, 2022 --AstraZeneca’s Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in China to reduce the risk of sustained estimated glomerular filtration rate (eGFR) declin……
NEW YORK, August 29, 2022 (GLOBE NEWSWIRE) – Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, t……
August 08, 2022, Pfizer Inc. (NYSE: PFE) and Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the companies have entered into a definitive agreement under which Pfizer will acquire GBT. Under the terms……
July 28, 2022--Incyte today announced that the U.S. Food and Drug Administration (FDA) has approved Opzelura? (ruxolitinib) cream 2.5% for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 22……
July 20, 2022- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) and granted Priority Review for Lunsumio? ……
June 23, 2022 —Novartis today announced the US Food and Drug Administration (FDA) granted accelerated approval for Tafinlar? (dabrafenib) + Mekinist? (trametinib) for the treatment of adult and pediatric patients 6 years……
Copyright Nanjing Dorra Pharmaceutical Technology Co.,Ltd. @ 2018 China All Rights Reserved 蘇ICP備12056923號-1
Tel: 025-82232955 025-82232966
Fax:025-82232933 025-82232944
E-mail: info@dorrapharma.com
